Actively Recruiting
Understanding Pancreas Function During and After Pregnancy in Women With Gestational Diabetes Mellitus Using Exendin 9-39 Infusion
Led by Mayo Clinic · Updated on 2026-09-08
90
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the human pancreas functions during and after pregnancy, focusing on women with and without gestational diabetes mellitus. This study aims to understand changes in pancreatic activity related to gestational diabetes to advance basic science knowledge in this area. The study is sponsored by Mayo Clinic and includes participants between 20 and 40 years old. Participants are divided into two groups pregnant women diagnosed with gestational diabetes mellitus and those without, matched by factors such as parity, age, ethnicity, gestational week at diagnosis, and first trimester body mass index. The study includes an intervention where Exendin 9-39 is given as an intravenous infusion during one postpartum study day to assess its effects alongside glucose infusion tests. Participants will undergo metabolic study visits during pregnancy at about 26 to 32 weeks gestation and again postpartum at 6 weeks to 3 months after delivery. These visits include measurements such as graded glucose infusion, glucagon secretion rate, insulin secretion response to glucose, and beta-cell responsivity. The primary outcome is the G50 measurement during these periods, with secondary outcomes focused on various aspects of pancreatic hormone secretion. The study lasts through pregnancy and postpartum follow-up, with ongoing data collection until 2030.
CONDITIONS
Brief Title
Islet Function in Gestational Diabetes
Research Team
J
Jeanette Laugen
A
Amy Zipse
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here